LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK)2.8 million injections of repackaged ...

LYTENAVATM is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Un ...

Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD. In the United States, ONS-5010/LYTENAVA™ is ...

AMD is still seeing strong data center sales. Fast-forward to today, and the biggest computing trend to ever occur, the AI ...

A CRN analysis found that Nvidia finished the first quarter with more than double the revenue of what Intel and AMD earned ...

A top executive at Advanced Micro Devices Inc. (NASDAQ: AMD) made a sizable open market purchase in the stock this week, ...

A massive insider purchase just hit Advanced Micro Devices (AMD), and it’s raising eyebrows across Wall Street. Philip Guido, ...

These include, among others, the success of Outlook Therapeutics' commercial launch of LYTENAVA™ in Germany ... the therapeutic potential of LYTENAVA™ as a treatment of wet AMD, expectations ...

AMD held a Computex press event to introduce its Radeon RX 9060 XT graphics cards and Threadripper CPUs for next-gen gaming and workstations.

In a landmark event that reaffirms its commitment to advancing Sri Lanka’s digital landscape, Lenovo, the global technology ...

At the same time, commercial PCs are turning out to be another key growth driver for AMD. Its sell-through of commercial PC processors was up by 30% from the year-ago period. That wasn't ...

In 2024, Nvidia’s revenue soared to $130.5 billion, with AI-driven data center sales accounting for nearly 80% of its growth, ...